Anthropic filed for its blockbuster IPO on Monday, bringing the AI behemoth closer to what could be the largest public debuts in stock market history. The 335-page filing revealed the Claude maker generated around $16.3 billion in revenue for the first half of the year, up from $1.2 billion a year earlier, but incurred a $80.7 billion net loss for the first half of the year (most of which is due to a non-cash accounting charge). The company touts more than 300,000 enterprise customers, 250 of which spend over $10 million on Anthropic’s products every year. It plans to list under the ticker symbol “ANT” and is on track to go public as soon as mid-November.
Forbes estimates that its two most prominent cofounders: CEO Dario Amodei and his sister, Anthropic president Daniela Amodei, are worth $13.6 billion and $13.7 billion, respectively. Each cofounder owns an estimated 1.4% stake.
AI Generated·May contain errors
Today on Forbes,
two big AI risks revealed in Anthropic's new S1 filing.
Anthropic officially filed
for an initial public offering, or IPO, on Monday.
That step brings it closer to what could be one
of the largest public debuts in stock market history.
The company is slated to go public in the coming weeks.
Anthropic's S1 filing on Monday
was the first glimpse public investors have gotten
into the AI firm's financials.
It also revealed numerous previously unknown aspects
of how the company functions and how
it views AI's role in society.
In the filing, it revealed that more than 90%
of the company's code was written by
its own AI tool, Claude, in September.
The AI giant is increasingly using its own AI models to research,
design, and develop
subsequent versions of its models,
a process it calls, quote, closing the loop.
In the S1, the company wrote, quote,
Claude itself has become one
of the most powerful drivers of our progress.
The company says that Claude runs experiments, generates training data,
and automates evaluations and safety audits.
It has also helped make algorithmic improvements
that allow Anthropic to use computing resources more efficiently.
According to the filing, Anthropic reported $16.3 billion in revenue
and $693 million in operating losses in the first six months of 2026.
In Q2 2026, its first profitable quarter,
it had $974 million in operating income.
It's not surprising
that Anthropic's 5,300-strong staff relies heavily on Claude,
but the company now spends more
on internal AI usage than it does on salaries.
According to the S1,
the value of Anthropic's internal Claude usage at list prices has
grown over 250 times from January 2026 to September 2026.
Thanks to Claude,
engineers contributed over 45 times more code per day in Q3 2026 than
in 2024.
But while Anthropic lists Claude's ability
to improve itself as one of its most, quote,
significant structural advantages, it also poses a major risk.
As Claude helps build future versions of itself,
it compresses timelines and accelerates the pace
of AI development.
Anthropix says in the S1 that a key risk is AI moving so fast
that it could outpace the company's ability
to develop corresponding safety and security measures.
Flaws or errors present in current versions of the model
could pass down into later ones, making them harder to detect and fix.
Anthropic isn't the only company using its own AI to train more AI.
Its rivals are doing it too.
To address these risks, Anthropic
is calling for an industry-wide initiative
to, quote, pace the frontier
and allow for independent safety reviews of all frontier models.
Anthropic expects to spend $1 billion over the next five years
to build, quote, external reviewer capacity with Accenture.
Meanwhile, Anthropic also trumpets its commitment
to using AI for scientific research
on the very first page of its IPO prospectus.
The introduction reads, quote,
We have started to directly make biological discoveries with Claude.
It notes that Anthropic expects the model
to make more breakthroughs in the future.
It's referring to the AI firm's own internal biology research,
announced last month, where its software discovered a new enzyme family
with properties similar to those used for CRISPR gene editing.
The company has also built a number of products for scientists,
including Clawed Science and
also Clawed for Life Sciences,
which aims to help in drug discovery research, as well
as helping to produce FDA submissions and similar paperwork.
And Anthropic has developed software
that enables AI agents to operate lab equipment,
quote, such as microscopes, liquid handlers,
and off-the-shelf robotic arms, to help automate
research, according to the filing.
It name-checks customers like
pharmaceutical giant Bristol-Myers Squibb,
the Garvin Institute of Medical Research,
and the University of California, San Francisco.
It earlier made headlines partnering with companies like Lilly
and Novo Nordisk.
Along with the potential rewards
of applying anthropics machine learning models to research
come significant risks, especially in the realm of scientific research.
That includes its model's ability to operate robots
and lab equipment, which it says, quote,
could result in bodily injury, property damage,
damage to costly equipment or experimental
materials, or the release of hazardous substances.
This could be due to misalignments in the models,
or deliberate misuse. Additionally,
the company warns that its models could be useful to people
Seeking to develop chemical, biological, or other dangerous weapons.
While Anthropic says it has deployed technical
safeguards against bad actors who want to make
weapons, it warns that, quote,
such safeguards are incomplete, may be outdated in light of
evolving threat models,
have been and may in the future again be circumvented, or may fail to
operate as intended.
For full coverage, check out Rashi Srivastava's and Alex Knapp's pieces
on Forbes.com. This is Kieran Meadows from Forbes.
Thanks for tuning in.